Announcement

Collapse
No announcement yet.

Clin Infect Dis. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Clin Infect Dis. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019


    Clin Infect Dis. 2020 Mar 28. pii: ciaa344. doi: 10.1093/cid/ciaa344. [Epub ahead of print]
    Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.


    Zhao J1, Yuan Q2,3, Wang H1, Liu W2,3, Liao X1, Su Y2,3, Wang X1, Yuan J4, Li T2,3, Li J5, Qian S1, Hong C2,3, Wang F4, Liu Y4,6, Wang Z6, He Q6, Li Z3, He B2,3, Zhang T2,3, Fu Y7, Ge S2,3, Liu L1,6, Zhang J2,3, Xia N2,3, Zhang Z1,6.

    Author information




    Abstract

    BACKGROUND:

    The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.
    METHODS:

    A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed.
    RESULTS:

    Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006).
    CONCLUSIONS:

    The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.
    ? The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.



    KEYWORDS:

    COVID-19; SARS-CoV-2; antibody


    PMID:32221519DOI:10.1093/cid/ciaa344

Working...
X